A recent study by researchers from REPROCELL found that IBD patients display different drug absorption profiles to healthy individuals. This is the first time that drug absorption has been estimated using inflamed GI tissue from this patient group. A similar study, performed by Keio University, estimated drug absorption in healthy areas of GI tissue from ulcerative colitis (UC) donors.
Glasgow, UK: REPROCELL (Biopta) today announced that they can predict test article permeability using gastrointestinal (GI) resections from Inflammatory Bowel Disease (IBD) donors. This service, which is first of its kind to market, will allow ADME/DMPK scientists to estimate compound permeability in living human IBD tissue.
BELTSVILLE, MD. (PRWEB) NOVEMBER 12, 2019: REPROCELL Inc. a stem cell and drug discovery company has announced today that they have been selected by Lantern Pharma to provided preclinical screening and drug sensitivity for its portfolio of oncology drugs. The collaboration is designed to obtain millions of data points using panels of unique and genetically edited cell lines from various tumors. The data generated from these studies will help Lantern’s AI platform to generate the biological and genetic basis for drug positioning and maximum drug efficacy. Lantern believes this will help bring oncology therapies to patients more efficiently and affordably than traditional R&D efforts.
Axion BioSystems, Inc., the world leader in multi-well microelectrode array (MEA) systems, has announced REPROCELL as the new distributor of its Maestro systems and consumables in Japan.
REPROCELL’s BioServe and Biopta tissue procurement networks combine to create a new service isolating human primary cells.
On Tuesday 20th March 2018 REPROCELL Europe Ltd’s CEO Dr David Bunton appeared in front of the Economy, Jobs and Fair Work Committee at the Scottish Parliament to discuss Scotland’s Economic performance. He was also joined by:
• Dr Diane Harbison, CEO, of Stratified Medicine Scotland
• Claire Mack, CEO, of Scottish Renewables
• Gareth Wynn, Stakeholder and Communications Director, Oil & Gas UK
REPROCELL’s Alvetex, a scaffold for 3D cell culture and bioengineered tissue models, is in the Durham University (UK) News yesterday, at https://www.dur.ac.uk/news/newsitem/?itemno=33385
Sign up to receive information from REPROCELL about our products, services, applications, promotions, and news (includes a weekly blog update email).